KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 86 filers reported holding KINNATE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,106 | -70.5% | 2,933 | -36.2% | 0.00% | – |
Q2 2023 | $13,938 | +4162.4% | 4,600 | -91.2% | 0.00% | – |
Q1 2023 | $327 | +16.4% | 52,373 | +13.7% | 0.00% | – |
Q4 2022 | $281 | -99.9% | 46,045 | +0.6% | 0.00% | -100.0% |
Q3 2022 | $547,000 | +0.9% | 45,773 | +6.6% | 0.00% | 0.0% |
Q2 2022 | $542,000 | +50.1% | 42,957 | +33.9% | 0.00% | – |
Q1 2022 | $361,000 | -32.6% | 32,079 | +6.0% | 0.00% | -100.0% |
Q4 2021 | $536,000 | -22.3% | 30,270 | +1.0% | 0.00% | 0.0% |
Q3 2021 | $690,000 | +91.7% | 29,972 | +93.9% | 0.00% | – |
Q2 2021 | $360,000 | -1.1% | 15,455 | +32.1% | 0.00% | – |
Q1 2021 | $364,000 | – | 11,697 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |